Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Letters

Generic controlled-release oxycodone

Philip A. Baer, Joel Bordman and Erica L. Weinberg
CMAJ October 01, 2013 185 (14) 1251-1252; DOI: https://doi.org/10.1503/cmaj.113-2134
Philip A. Baer
Chair, Section on Rheumatology, Ontario Medical Association, Toronto, Ont., and Member of Executive, Ontario Rheumatology Association, and Editor-in-Chief, (Baer), Newmarket, Ont.; Medical Director, Complex Pain Program, First Steps Clinics, Toronto, Ont. (Bordman); and physician (Weinberg), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joel Bordman
Chair, Section on Rheumatology, Ontario Medical Association, Toronto, Ont., and Member of Executive, Ontario Rheumatology Association, and Editor-in-Chief, (Baer), Newmarket, Ont.; Medical Director, Complex Pain Program, First Steps Clinics, Toronto, Ont. (Bordman); and physician (Weinberg), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erica L. Weinberg
Chair, Section on Rheumatology, Ontario Medical Association, Toronto, Ont., and Member of Executive, Ontario Rheumatology Association, and Editor-in-Chief, (Baer), Newmarket, Ont.; Medical Director, Complex Pain Program, First Steps Clinics, Toronto, Ont. (Bordman); and physician (Weinberg), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

We wish to respond to Miller’s article in CMAJ.1 The US Food and Drug Administration (FDA) approved abuse-deterrent labelling for reformulated OxyContin in the United States. The new labelling indicates that the product has physical and chemical properties that are expected to make abuse via injection difficult and to reduce abuse via the intranasal route (snorting). In addition, the FDA determined that the original OxyContin was withdrawn from sale for reasons of safety or effectiveness and, accordingly, the agency will not accept or approve any abbreviated new drug applications (generics) that rely upon the approval of the original OxyContin.2

All available postmarketing assessments of the impact of reformulated OxyContin (OxyNEO in Canada) on abuse, as well as the FDA’s draft Guidance for Industry: Abuse-Deterrent Opioids — Evaluation and Labeling,3 were available to former federal health minister Leona Aglukkaq.

We are not in the market for a revival of the “cross-border controlled-release oxycodone shopping” that was observed near the Detroit–Windsor Tunnel between August 2010 and October 2011, at a time when the original OxyContin remained available in Canada and the reformulated OxyContin had been introduced in the US.4

The FDA has now provided the evidence-based guidance former minister Aglukkaq alluded to in her March 2013 letter to the Commissioner of the FDA. The health minister now needs to protect the health and safety of all our communities and take concrete action to reduce risk by removing generic controlled-release oxycodone from the Canadian market.

Footnotes

  • Competing interests: Erica Weinberg: Janssen, Lilly, Medical Futures Inc., Purdue Pharma, Valeant; Philip Baer: Janssen, Purdue Pharma; Joel Bordman: Janssen, Purdue Pharma, Pfizer, Nycomed, Paladin Labs, King Pharma Lilly, Bayer, Schering-Plough, Valeant, Boehringer Ingelheim

References

  1. ↵
    1. Miller A
    . Aglukkaq asks for US help to control oxycodone CMAJ 2013;185:E317–8.
    OpenUrl
  2. ↵
    FDA approves abuse-deterrent labeling for reformulated OxyContin [media release]. Silver Spring (MD): US Food and Drug Administration; 2013. Available: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm348252.htm (accessed 2013 May 10).
  3. ↵
    Guidance for industry: abuse-deterrent opioids — evaluation and labeling. Silver Spring (MD): US Food and Drug Administration; 2013. Available: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743 (accessed 2013 May 10).
  4. ↵
    1. Gomes T,
    2. Paterson MJ,
    3. Juurlink DN,
    4. et al
    . Reformulation of controlled-release oxycodone and pharmacy dispensing patterns near the US–Canada border. Open medicine 2012;4. Available: www.openmedicine.ca/article/view/566 (accessed 2013 May 10).
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 185 (14)
CMAJ
Vol. 185, Issue 14
1 Oct 2013
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Generic controlled-release oxycodone
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Generic controlled-release oxycodone
Philip A. Baer, Joel Bordman, Erica L. Weinberg
CMAJ Oct 2013, 185 (14) 1251-1252; DOI: 10.1503/cmaj.113-2134

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Generic controlled-release oxycodone
Philip A. Baer, Joel Bordman, Erica L. Weinberg
CMAJ Oct 2013, 185 (14) 1251-1252; DOI: 10.1503/cmaj.113-2134
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Coexisting failures do not diminish the stature of a giant
  • Dare we hope
  • Highlighting obesity as a risk factor for endometrial cancer
Show more Letters

Similar Articles

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire